The Roundup weedkiller litigation has entered a tense new phase as plaintiffs and attorneys battle over Bayer’s proposed $7.25 billion settlement plan. Instead of helping to resolve the long-running Roundup cancer lawsuits, the agreement is now facing mounting objections about what the settlement really means.
Many plaintiffs, their attorneys, and critics claim the multi-billion-dollar deal unfairly limits future lawsuits, while at the same time, benefits lawyers and Bayer more than victims. They believe that future plaintiffs could effectively lose important rights, including access to jury trials or the ability to prove in court the pesticide is the cause of their cancer.
The settlement challenge comes amidst growing concerns about how much Roundup settlements are actually worth, and why some victims might not get paid. But this dispute highlights an unusual moment in mass tort litigation, too.
Victims are not just fighting the product’s manufacturer; many are fighting other plaintiffs’ attorneys involved in negotiating the Roundup settlement.
Several attorneys have also filed to move the dispute to federal court. They believe doing so may provide broader oversight, increased procedural protections, and greater scrutiny of how future Roundup claims are handled.
Why are Roundup Cancer Victims Challenging the Roundup Settlement?
More than a decade ago, the World Health Organization classified glyphosate, an active ingredient in Roundup, as probably carcinogenic to humans. However, Bayer has consistently denied that the weedkiller causes serious health effects.
The company has spent years defending themselves against tens of thousands of lawsuits that allege Roundup exposure causes non-Hodgkin lymphoma (NHL) and other cancers. Despite those denials, Bayer has already paid billions to settle cancer claims and they’re still facing over 65,000 lawsuits across the U.S.
The newest Roundup settlement proposal, which was announced in February, was created to resolve both existing and future cancer claims. It’s the future plaintiffs – those who haven’t filed lawsuits, may not know their cancer is connected to glyphosate-based pesticides, or have yet to develop an illness from exposure to it – are what makes the agreement so controversial.
The attorneys that formally objected the Roundup settlement by filing a notice of removal on May 22 allege the deal was the result of collusion. They argue that Roundup lawyers are set to receive $675 million in fees, which is over 9% of the total $7.25 billion deal, and that the case belongs in federal court instead of state court.
Critics say the proposal would create barriers for future Roundup cancer victims by forcing their lawsuits into a system that could make it more difficult to be compensated and limit the ability to pursue jury trials. They also claim the structure could reduce Bayer’s long-term legal exposure while locking vulnerable plaintiffs a tiered settlement structure they never approved.
What’s uncommon about this scenario is that major mass tort litigation doesn’t typically result in significant division among plaintiffs and lawyers. Some attorneys support the proposal as a way to avoid years of additional Roundup litigation and finally provide victims with compensation. Others argue it undermines core legal rights for future Roundup cancer plaintiffs.
Why the Roundup Settlement Fight Matters Beyond Existing Victims
The Roundup settlement objections could shape the future of mass tort litigation well beyond the battle with Bayer. It reflects a growing trend of wealthy companies increasingly attempting to resolve claims for future plaintiffs before they’ve even been diagnosed with an illness.
Critics of this approach argue it creates serious ethical and legal concerns. From their perspective, individuals who don’t know they’ve been harmed by a product are unknowingly surrendering rights tied to health effects that can take years to develop. Not to mention, it can take even longer to learn such illnesses could have been caused by exposure to a dangerous product.
For consumers, this raises important questions surrounding whether corporations should be allowed to negotiate limits on future lawsuits. Experts believe that how the Roundup settlement fight is handled may ultimately influence how other mass torts, like the current PFAS firefighting foam, are resolved.
The dispute also highlights growing frustration among some plaintiffs over the economics of mass tort litigation itself. Large settlements can generate enormous attorney fees. The Roundup cancer settlement is a prime example. Meanwhile, individual victims receive far less compensation than expected after deductions, liens, and administrative costs.
The tension raised by the details of the deal is becoming more visible as recent public court filings challenge the Roundup settlement.
What Comes Next for the Roundup Cancer Lawsuits?
The objections to Bayer’s proposed $7.25 billion settlement are expected to trigger months of additional court proceedings. It will take some time for judges to evaluate whether the proposed framework is fair to future claimants.
While those considerations occur, the Roundup lawsuits will continue to move forward nationwide. Bayer still faces substantial liability exposure despite previous settlements and favorable defense verdicts in some recent trials.
For plaintiffs diagnosed with non-Hodgkin lymphoma after using Roundup, the legal battle remains active. Experts says individuals should pay close attention to how the settlement challenge based on claims of collusion and unfairness to future victims unfolds.
The outcome may determine more than just what happens with victims harmed by the weedkiller. With Roundup still being used today and the fact that it can takes years, if not longer, to develop an associated illness, what the courts decide will show if companies are allowed to place broader limits on future injury lawsuits involving dangerous products.
It’s clear that the pesticide isn’t going anywhere. In fact, Trump ordered increased production of glyphosate, even though many other countries feel there’s significant evidence of the dangers of the Roundup ingredient. It’s likely we’ll see many more weedkiller lawsuits in the coming decades.
But as the legal battle intensifies, the Roundup cancer lawsuits are evolving from a dispute over health effects into a larger debate about fairness and corporate accountability – and who truly benefits from billion-dollar mass tort settlements.
